ArticleScientific reports2025
In silico and in vivo assessment of the immunostimulatory activity of palmitic acid derived from Vernonia amygdalina.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vernonia amygdalina is rich in palmitic acid (PA), a bioactive known for its anti-inflammatory capabilities. Yet, there is a paucity of scientific information on the immunostimulatory effect of the compound on the immune response. Therefore, this study assessed the potential of PA to modulate the immune cell function with potential implications in immune-mediated diseases. Bioinformatic techniques, including retrieval of regulatory cytokine structure and PA, molecular docking, and visualisations, were conducted using Protein Databank, PubChem database, Chimera, PyRx, and Biovia Discovery studio software. To assess the cell-mediated immune response in vivo, sheep red blood cells (SRBCs) were administered intraperitoneally to Mus musculus (mice). This was followed by PA treatments at various concentrations. Paw thickness and phagocytic activity and index were measured at intervals. Furthermore, the primary and secondary antibody titres were measured to assess the humoral immune response as a follow-up to the SBRC and PA treatments at varying concentrations. PA bound favourably with the cytokines, including TNF-α, IFN-γ, IL-12, IL-6, TGF-β, and IL-10, showing a binding affinity score range of - 6.1 kcal/mol to - 3.5 kcal/mol. In the mouse model, PA-treated groups of 2 and 5 mg/kg showed a significant increase in paw thickness, whereas no significant change was observed at 10 mg/kg. Furthermore, PA induced a significant increase in macrophage phagocytic index and activity in a dose-dependent manner. The PA-treated group of 10 mg/kg showed the highest primary humoral response, while no significant changes were observed in secondary responses. Overall, the potential of palmitic acid to immunomodulate the innate and cell-mediated immunity in a dose-dependent manner with limited effect on antibody-mediated immune response holds promising benefit to treat inflammatory diseases and enhance vaccine efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.